Sulfuric acid--17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol--water (1/1/5) | 66591-53-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: Sulfuric acid--17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol--water (1/1/5)
• 英文别名: (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;sulfuric acid;pentahydrate
• CAS: 66591-53-5
• 化学式: C17H31NO12S
• 分子量: 473.5
• InChiKey: XJIXIEBYTLLFCV-FAISOMDOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.58
• 重原子数：
  31
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  141
• 氢给体数：
  9
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  Sulfuric acid--17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol--water (1/1/5) 、 三氟甲烷磺基苯胺 、 三乙胺 在 碳酸氢钠 、 二氯甲烷 、 Brine 、 Sodium sulfate-III 、 silica gel 、 methanol-dichloromethane 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以to afford 703 mg of the title compound as a white solid (62% yield)的产率得到3-Trifluoromethanesulfonyl morphine
  参考文献：
  名称：

  SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS

  摘要：

  本文描述了含氟有机化合物及制备含氟有机化合物的方法，例如使用钯配合物。本文还描述了含有本文所述化合物和钯配合物的组合物和试剂盒。

  公开号：

  US20110054175A1
• 作为产物：
  描述：

  吗啡 、 硫酸 以 水 为溶剂， 生成 Sulfuric acid--17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol--water (1/1/5)
  参考文献：
  名称：

  Morphine Sulfate Methanolic Solvate, Processes for Making Same and Related Compositions and Methods for Treating Pain

  摘要：

  减少含有吗啡材料中杂质，特别是α，β-不饱和酮（ABUK）的过程。还描述了新的化合物，即低ABUK吗啡硫酸盐甲醇溶剂和新的晶体形式。制备吗啡硫酸盐甲醇溶剂的方法包括将吗啡自由碱组成物与甲醇混合形成溶液，并向溶液中加入含硫酸的液体，以形成吗啡硫酸盐甲醇溶剂沉淀。制备吗啡硫酸盐化合物的方法包括在水蒸气存在下干燥吗啡硫酸盐甲醇溶剂，使甲醇分子被去除并被水蒸气分子替换。用于治疗疼痛的组合物包括吗啡硫酸盐化合物和至少一种药用可接受的赋形剂。治疗疼痛的方法包括向需要该组合物的患者施用包含吗啡硫酸盐化合物和至少一种药用可接受的赋形剂的组合物。

  公开号：

  US20150361084A1

文献信息

• CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT
  申请人：Hemmingsen Pernille Hoyrup

  公开号：US20100239667A1

  公开（公告）日：2010-09-23

  Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof. the solid inner layer being sandwiched between two outer layers B1) and B2), each outer layer comprising iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B, the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more tapered ends, wherein the ratio between the surface area of one end surface of the cylinder and the length of the cylinder is in a range of from 0.02 to 45 mm.

  分层制药组合物，适用于口服治疗吸收发生在胃肠道大部分的疾病。该组合物包括A) 一个固体内层，其中包括i) 一种活性物质，和ii) 一种或多种分散剂/爆炸剂，一种或多种泡腾剂或其混合物。该固体内层被夹在两个外层B1)和B2)之间，每个外层包括iii) 一种或多种水溶性和/或结晶聚合物，或者水溶性和/或结晶聚合物的混合物，聚合物为聚乙二醇，形式为a) 分子量至少为约100,000道尔顿的同聚物，和b) 分子量至少为约2,000道尔顿的共聚物，或其混合物，和iv) 一种活性物质，其与所述固体内层A)中的活性物质相同，且层A与层B不同，该分层组合物被涂覆有一种涂层C)，该涂层具有至少一个开口，暴露出至少一个外层的表面，该涂层在液体中具有相当的不溶性和不透性，包括一种聚合物，该组合物具有圆柱形状，可选地具有一个或多个锥形端部，其中圆柱体的一个端面的表面积与圆柱体的长度之比在0.02至45毫米的范围内。
• IMPLANTS FOR POSTOPERATIVE PAIN
  申请人：Palasis Maria

  公开号：US20130071463A1

  公开（公告）日：2013-03-21

  Medical implants and methods useful in treating postoperative pain are described. The implants comprise one or more electrospun drug-loaded fibers, which fibers comprise a drug useful in the treatment of pain. The implants are implanted at sites of interest including joint capsules, bones, and subcutaneous spaces, and are secured with tissue flaps or fasteners.

  本文描述了用于治疗术后疼痛的医疗植入物和方法。这些植入物包括一种或多种电纺药物载荷纤维，这些纤维包含一种有益于治疗疼痛的药物。这些植入物被植入到关节囊、骨骼和皮下空间等感兴趣的部位，并通过组织瓣或紧固件固定。
• Controlled release pharmaceutical compositions for prolonged effect
  申请人：Hemmingsen Pernille Hoyrup

  公开号：US08821928B2

  公开（公告）日：2014-09-02

  Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof. the solid inner layer being sandwiched between two outer layers B1) and B2), each outer layer comprising iii) a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one of a) a homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at least about 2,000 daltons, or a mixture thereof, and iv) an active substance, which is the same as in said solid inner layer A), and layer A being different from layer B, the layered composition being coated with a coating C) that has at least one opening exposing at least one surface of said outer layer, the coating being substantially insoluble in and impermeable to fluids and comprising a polymer, and the composition having a cylindrical form optionally with one or more tapered ends, wherein the ratio between the surface area of one end surface of the cylinder and the length of the cylinder is in a range of from 0.02 to 45 mm.

  分层药物组合物适用于口服治疗吸收发生在胃肠道大部分的疾病。该组合物包括A）固体内层，包括i）活性物质，和ii）一个或多个分散剂/爆炸剂，一个或多个泡腾剂或其混合物。固体内层被夹在两个外层B1）和B2）之间，每个外层包括iii）一种或多种基本上水溶性和/或结晶性聚合物，或基本上水溶性和/或结晶性聚合物的混合物，聚合物是一种聚乙二醇，形式为a）分子量至少约100,000道尔顿的均聚物，和b）分子量至少约2,000道尔顿的共聚物，或其混合物，以及iv）一种活性物质，该活性物质与所述固体内层A）中的活性物质相同，且层A与层B不同，分层组合物被涂覆有涂层C），该涂层具有至少一个开口，暴露至少一个所述外层的表面，该涂层在液体中基本上不溶且不透水，并包括一种聚合物，该组合物具有圆柱形式，可选地具有一个或多个锥形端部，其中圆柱体的一端表面的表面积与圆柱体的长度之比在0.02至45毫米的范围内。
• Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
  申请人：Johnson Matthey Public Limited Company

  公开号：US09127008B2

  公开（公告）日：2015-09-08

  Processes for reducing the amount of impurities, especially α,β-unsaturated ketones (ABUK), in materials containing morphine. Novel compounds, namely low ABUK morphine sulfate methanolic solvate, and a novel crystal form are also described. The method for making morphine sulfate methanolic solvate comprises mixing a morphine free base composition with methanol to form a solution and adding a liquid comprising sulfuric acid to the solution to form a morphine sulfate methanolic solvate precipitate. A method of making a morphine sulfate compound comprises drying the morphine sulfate methanolic solvate in the presence of water vapor, such that methanol molecules are removed and replaced with water vapor molecules. A composition for treating pain comprises the morphine sulfate compound and at least one pharmaceutically acceptable excipient. A method for treating pain comprises administering to a patient in need thereof the composition comprising the morphine sulfate compound and at least one pharmaceutically acceptable excipient.

  减少含有吗啡的材料中杂质，尤其是α，β-不饱和酮（ABUK）的方法。还描述了一种新型化合物，即低ABUK吗啡硫酸盐甲醇溶剂和一种新型晶体形式。制备吗啡硫酸盐甲醇溶剂的方法包括将吗啡无水基组合物与甲醇混合形成溶液，并添加含有硫酸的液体到溶液中形成吗啡硫酸盐甲醇溶剂沉淀。制备吗啡硫酸盐化合物的方法包括在水蒸气的存在下干燥吗啡硫酸盐甲醇溶剂，以去除甲醇分子并用水蒸气分子替换。用于治疗疼痛的组合物包括吗啡硫酸盐化合物和至少一种药学上可接受的辅料。治疗疼痛的方法包括向需要治疗的患者施用包含吗啡硫酸盐化合物和至少一种药学上可接受的辅料的组合物。
• 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE
  申请人：ALERE SAN DIEGO, INC.

  公开号：US20160022809A1

  公开（公告）日：2016-01-28

  The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.

  本发明涉及新型6-乙酰基吗啡类似物，以及它们的合成和使用方法。这些类似物旨在提供方便的连接化学反应，以在温和条件下与目标蛋白质、多肽、固相或可检测标记上的适当基团耦合。